Ludwig Boltzmann Institute Arthritis and Rehabilitation

What Ludwig Boltzmann Institute Arthritis and Rehabilitation does

The Ludwig Boltzmann Institute Arthritis and Rehabilitation (LBIAR) is a Vienna-based, non-profit applied research institute within the Ludwig Boltzmann Gesellschaft, hosted at the Medical University of Vienna and led since 2021 by Scientific Director Tanja Stamm. Its mission is to advance the understanding, treatment, and rehabilitation of osteoarthritis (OA) and related musculoskeletal and pain conditions through clinical, translational, and methodological research.

LBIAR operates research programs across at least seven Austrian sites (Vienna, two in Graz, Salzburg, Saalfelden, Gröbming, and Baden) in partnership with the Medical University of Vienna, PVA patient organization, and ÖGK public health insurer. Core research assets include the BLOAR longitudinal patient registry, the BLOAR biobank, and the AKAPP clinical study, which together generate clinical, imaging, and molecular data on OA progression. The institute has developed joint-on-a-chip and animal-free synovial membrane biochip platforms and applies AI/deep-learning methods to quantitative MRI cartilage analysis, including through a spin-off relationship with Chondrometrics GmbH and a 2024–2025 partnership with Formation Bio for AI-driven drug development.

The institute is funded primarily through public research grants via Ludwig Boltzmann Gesellschaft and Austrian federal sources, supplemented by partnerships and academic collaborations; it does not operate a commercial revenue model. Scientific recognition includes the 2026 Austrian Staatspreis for animal-free research methods, the 2024 OARSI National Ambassador award to its director, and the 2010 OARSI Clinical Research Award to former director Günter Steiner.

Name

Ludwig Boltzmann Institute Arthritis and Rehabilitation

Legal name

Ludwig Boltzmann Institut für Arthritis und Rehabilitation

Website

https://ar.lbg.ac.at

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

The Ludwig Boltzmann Institute Arthritis and Rehabilitation is a Vienna-based non-profit research institute focused on osteoarthritis, musculoskeletal disorders, pain, and rehabilitation, operating clinical and translational research programs across multiple Austrian sites.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Scientific Research and Development Services (5417), Offices of Physical, Occupational and Speech Therapists, and Audiologists (62134), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

Orthopedic Physical Therapy & Post-Op Rehab (HSADAIAA)

Keywords

• Musculoskeletal research
• Osteoarthritis research
• Rehabilitation research
• Clinical outcome research
• Medical imaging biomarkers

Headquarters

HQ city

Vienna

HQ country

Austria

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel

Distribution channels2 records

Marketing channels5 records

Core offering

The Ludwig Boltzmann Institute for Arthritis and Rehabilitation is a non-profit research institute conducting translational and clinical research on musculoskeletal disorders, with primary focus on osteoarthritis, pain, and rehabilitation. Its core deliverables include nationwide cohort studies (AKAPP), the BLOAR patient registry and biobank, AI/deep-learning quantitative MRI imaging biomarkers for articular cartilage, joint-on-a-chip and animal-free synovial membrane biochip models for disease research, and applied rehabilitation outcome research including CIMT and the RehaJet program.

Product overview

The Ludwig Boltzmann Institute for Arthritis and Rehabilitation is a research institute (not a commercial product company) conducting research into the causes, mechanisms, and consequences of musculoskeletal disorders, with particular focus on osteoarthritis (OA), pain, and rehabilitation. Their portfolio includes research programs in osteoarthritis pathophysiology, quantitative musculoskeletal imaging using AI/Deep Learning, clinical studies (AKAPP, BLOAR registry with biobank), rehabilitation research (CIMT, RehaJet), and advanced joint-on-a-chip platforms for disease modeling. Research spans from basic molecular and cellular research through translational research to clinical and patient-centred outcome research.

Differentiator

Problem solved

Functional benefit

Products and services

• Osteoarthritis Research Program

Quantifiable outcome

• Development of a validated fully automated cartilage T2 relaxation time analysis method using deep learning AI, clinical validation completed.
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Pensionsversicherungsanstalt Österreich (PVA)coreStrategic or Co-development PartnerPVA (Austrian Pension Insurance) is a key strategic partner for applied rehabilitation research. The partnership enables the AKAPP study on knee osteoarthritis and the BLOAR registry at rehabilitation centers in Saalfelden and Gröbming, with systematic data collection across over 1,000 patients for longitudinal outcome analyses.
• Österreichische Gesundheitskasse (ÖGK)coreStrategic or Co-development PartnerÖGK is the Austrian Health Insurance provider and a strategic partner supporting rehabilitation research activities and healthcare delivery related to musculoskeletal disorders.
• Medizinische Universität Wien (MUW)coreStrategic or Co-development PartnerMedUni Vienna hosts the Division of Rheumatology, Department of Orthopaedics and Trauma Surgery, and the Center for Medical Data Science (CeDAS) / Institute for Outcomes Research, which serve as the primary academic home for the institute's leadership and core research programs.
• Medizinische Universität Graz (MUG)coreStrategic or Co-development PartnerMedUni Graz hosts the Orthopaedic Research Laboratory for translational osteoarthritis research, led by Birgit Lohberger, focused on isolation of primary juvenile and OA cartilage cells from human tissue donations for 2D and 3D cell culture studies.
• Paracelsus Medizinische Universität (PMU), SalzburgcoreStrategic or Co-development PartnerPMU Salzburg hosts the Institute of Physiology and Pathophysiology, the Gastein Research Institute, and the Center for Anatomy and Cell Biology with the Musculoskeletal Imaging research program led by Felix Eckstein, integrating fundamental and clinical research in Salzburg.
• Universität GrazcoreStrategic or Co-development PartnerThe Institute for Pharmaceutical Sciences, Department of Pharmacology/Toxicology at Universität Graz hosts research on H2S-releasing NSAIDs and epigenetic drugs for osteoarthritis and osteoporosis treatment, under the leadership of Burkhard Klösch.
• Professor Frank BeiercoreOthersProfessor Frank Beier serves on the Scientific Advisory Board as Professor and Chair, Department of Physiology and Pharmacology, Canada Research Chair in Musculoskeletal Research, Western Bone and Joint Institute, University of Western Ontario, Canada. Provides international scientific oversight and guidance.
• Professor Ingvild KjekencoreOthersProfessor Ingvild Kjeken serves on the Scientific Advisory Board as Professor in Occupational Therapy, Norwegian National Advisory Unit on Rehabilitation in Rheumatology (NKRR), REMEDY Center for Treatment of Rheumatic and Musculoskeletal Diseases, Diakonhjemmet Hospital, Norway. Provides expertise in rehabilitation and rheumatology.
• Doctor Pascal de JongcoreOthersDoctor Pascal de Jong serves on the Scientific Advisory Board as Associate Professor and Rheumatologist, Department of Rheumatology, EULAR Centre of Excellence in Rheumatology, Erasmus University, Rotterdam, The Netherlands. Provides clinical rheumatology expertise and international perspective.
• Tauernklinikum Zell am See (TK)minorStrategic or Co-development PartnerCollaborative project with Tauernklinikum Zell am See investigating osteoarthritis as a secondary condition following joint trauma using biomarker and MRI analyses, with Wolfgang Wirth and Felix Eckstein contributing MRI analysis expertise.
• Chondrometrics GmbHcoreStrategic or Co-development PartnerA spin-off company co-founded by Felix Eckstein to translate academic imaging biomarker science into clinical trial solutions. Provides MRI-based quantitative analysis services for osteoarthritis clinical trials, integrating research findings from the institute into commercial applications.
• Formation BiominorStrategic or Co-development PartnerFormation Bio, owner of a potentially disease-modifying OA drug (Sprifermin), collaborated with Felix Eckstein and Wolfgang Wirth on MRI analysis of cartilage thickness in the FORWARD clinical trial.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Versus Arthritis: UK-based charity funding and conducting musculoskeletal and arthritis research with a similar translational, patient-centered model. Comparable as a mission-aligned arthritis research organization with biobank and clinical study infrastructure.
• Chondrometrics GmbH: A spin-off co-founded by LBIAR's imaging leadership to commercialize MRI-based quantitative cartilage analysis for OA clinical trials. Closest peer given shared technology, leadership lineage, and customer overlap with osteoarthritis drug developers.
• Kolling Institute (University of Sydney): University-hosted medical research institute with strong musculoskeletal and arthritis research programs. Directly comparable as an academic research entity integrating basic, translational, and clinical MSK research.

Others

• EULAR (European Alliance of Associations for Rheumatology): Pan-European rheumatology society coordinating research, guidelines, and Centers of Excellence in MSK disease. Relevant as an ecosystem partner rather than a competitor, given LBIAR's leadership engagement and EULAR-aligned research themes.

Emerging players

• Nordic Bioscience: Denmark-based biomarker company developing biochemical markers for osteoarthritis and musculoskeletal diseases, including PRO-C2 and ARGS. Comparable in its focus on validated OA biomarkers and imaging-adjacent endpoints for clinical trials.
• Rottapharm Biotech: Italy-based R&D biotech historically developing disease-modifying osteoarthritis drugs (e.g., sprifermin history). Comparable as a European DMOAD developer who would be a natural customer for LBIAR's imaging biomarkers and OA expertise.
• TissueGnostics GmbH: Austria-based developer of tissue and cell analysis solutions including biochip and high-content imaging platforms. Adjacent peer in microphysiological systems and AI-driven tissue analysis overlapping with LBIAR's joint-on-a-chip work.

Broad incumbents

• Hospital for Special Surgery (HSS Research Institute): Major US orthopedic and rheumatology research institution with deep OA, imaging, and rehabilitation programs. Comparable as a much larger orthopedic research body whose scientific agenda overlaps with LBIAR's core themes.
• NIAMS (NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases): US federal institute funding and conducting large-scale musculoskeletal and arthritis research. Comparable as the largest public-sector counterpart to LBIAR's mission scope and translational OA research portfolio.
• Karolinska Institutet (Rheumatology Unit): Sweden's leading medical university with internationally recognized rheumatology and musculoskeletal research groups. Comparable as an academic rheumatology/MSK research environment publishing in the same high-impact journals.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ludwig-boltzmann-institute-arthritis-and-rehabilitation

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ludwig Boltzmann Institute Arthritis and Rehabilitation